CHU de Grenoble - Hôpital Michallon

The vascular medicine service at CHU de Grenoble - Hôpital Michallon is conducting research aimed at improving prevention and treatment of blood‑clot related conditions. The focus is on patients who have experienced a venous thromboembolism and are at risk of recurrence.

• Assessing the safety and tolerability of a novel RNA‑based therapy for clot prevention
• Evaluating the impact of Factor XI inhibition on clot resolution
• Exploring strategies to reduce post‑thrombotic complications

This work seeks to advance therapeutic options that could lower the need for long‑term anticoagulation and improve quality of life for those with cardiovascular disease.

In the realm of blood‑cell disorders, the department is testing a targeted oral inhibitor for patients with systemic mastocytosis whose symptoms remain uncontrolled despite standard care.

• Oral masitinib versus placebo in indolent systemic mastocytosis
• Measuring symptom relief and disease stability
• Improving patient‑reported outcomes in rare mast cell disease

The trial aims to provide a new disease‑modifying option for this rare condition and to clarify its safety profile.

The site’s oncology research concentrates on aggressive blood cancers, specifically acute myeloid leukemia, evaluating a novel anthracycline analogue combined with standard chemotherapy.

• L‑Annamycin plus cytarabine as second‑line therapy
• Determining remission rates in relapsed AML
• Comparing efficacy against standard treatment

By identifying an optimal dosing strategy, the study hopes to increase complete remission rates for patients with limited treatment options.